Researchers Use Open Medical Network to Analyze Canine Health
CAMBRIDGE, Mass. — (April 1, 2012) — PatientsLikeMe (www.patientslikeme.com), the leading online community
for people with life-changing conditions, announces the opening of its doors to canines. The initial launch will be open only to dogs (Canis lupus familiaris). Future releases will allow participation of wolves, jackals, coyotes, and foxes. By sharing information about their symptoms and treatments, dogs will be able to find others just like them. Initial outcomes include urinary and barking frequency, feedings per day, indoor vs outdoor hours, and average time spent outdoors before urination and/or defecation.
“With 78 million dogs in the country, and potentially 5 million dogs who are sniffing around for what seems like hours, there is an unique opportunity to use the power of our open medical network to understand this issue and accelerate the validation and development of new biomarkers.” says Jamie Heywood, co-founder and chairman of PatientsLikeMe. There are currently more than 7,000 dogs in the PatientsLikeMe dog community sharing meaningful data which researchers are using to analyze and understand canine health.
Heywood will announce the new Dog community on stage at the Westminster Dog Show this fall. DogsLikeMe is the first of many animal communities to be launched by PatientsLikeMe, which, in addition to the 7,000 dogs, now boasts more than 140,000 humans sharing health data on treatments, symptoms and outcomes. More canine communities will be added in the coming months. A common cat (Felis silvestris catus) community will be launched in the fall. Feline and canine communities will not be allowed to interact in the forum.
PatientsLikeMe® (www.patientslikeme.com) is the world’s leading online health data sharing platform. PatientsLikeMe® creates new knowledge by charting the real-world course of disease through the shared experiences of patients. While patients interact to help improve their outcomes, the data they provide helps researchers learn how these diseases act in the real world and accelerate the discovery of new, more effective treatments.